カテゴリー： Market Monitor Global, 世界, 医療/バイオ

シクロホスファミド注射の世界市場見通し2023年-2029年

◆英語タイトル：Cyclophosphamide Injection Market, Global Outlook and Forecast 2023-2029
	◆商品コード：MMG23LY8444 ◆発行会社（リサーチ会社）：Market Monitor Global ◆発行日：2023年7月（※2025年版があります。お問い合わせください。） ◆ページ数：74 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル ◆産業分野：医薬品＆ヘルスケア

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥468,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥608,400	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥702,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Cyclophosphamide Injection Market 調査レポートは次の情報を含め、グローバルにおけるのシクロホスファミド注射市場規模と予測を収録しています。・世界のシクロホスファミド注射市場：売上、2018年-2023年、2024年-2029年
・世界のシクロホスファミド注射市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のシクロホスファミド注射市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「高用量」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

シクロホスファミド注射のグローバル主要企業は、Baxter、 Novartis、 Amneal Pharmaceuticals、 Aurobindo Pharma、 Zydus Cadila、 Pfizer、 Athenex、 GLS Pharma、 NorthStar Rx LLC、 Jiangsu Hengrui Medicine、 Getwell Oncology、 Ingenusなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、シクロホスファミド注射のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界のシクロホスファミド注射市場：タイプ別、2018年-2023年、2024年-2029年
世界のシクロホスファミド注射市場：タイプ別市場シェア、2022年
・高用量、低用量

世界のシクロホスファミド注射市場：用途別、2018年-2023年、2024年-2029年
世界のシクロホスファミド注射市場：用途別市場シェア、2022年
・がん、自己免疫疾患、ALアミロイドーシス、その他

世界のシクロホスファミド注射市場：地域・国別、2018年-2023年、2024年-2029年
世界のシクロホスファミド注射市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業におけるシクロホスファミド注射のグローバル売上、2018年-2023年
・主要企業におけるシクロホスファミド注射のグローバル売上シェア、2022年
・主要企業におけるシクロホスファミド注射のグローバル販売量、2018年-2023年
・主要企業におけるシクロホスファミド注射のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Baxter、 Novartis、 Amneal Pharmaceuticals、 Aurobindo Pharma、 Zydus Cadila、 Pfizer、 Athenex、 GLS Pharma、 NorthStar Rx LLC、 Jiangsu Hengrui Medicine、 Getwell Oncology、 Ingenus

*************************************************************

・調査・分析レポートの概要
シクロホスファミド注射市場の定義
市場セグメント
世界のシクロホスファミド注射市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のシクロホスファミド注射市場規模
世界のシクロホスファミド注射市場規模：2022年 VS 2029年
世界のシクロホスファミド注射市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのシクロホスファミド注射の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のシクロホスファミド注射製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：高用量、低用量
シクロホスファミド注射のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：がん、自己免疫疾患、ALアミロイドーシス、その他
シクロホスファミド注射の用途別グローバル売上・予測

・地域別市場分析
地域別シクロホスファミド注射市場規模 2022年と2029年
地域別シクロホスファミド注射売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Baxter、 Novartis、 Amneal Pharmaceuticals、 Aurobindo Pharma、 Zydus Cadila、 Pfizer、 Athenex、 GLS Pharma、 NorthStar Rx LLC、 Jiangsu Hengrui Medicine、 Getwell Oncology、 Ingenus
...

Cyclophosphamide injection is a cytotoxic drug used to treat malignant diseases in adults and children. Mainly used for malignant lymphoma, breast cancer, leukemia, metastatic or non-metastatic malignant solid tumors, progressive autoimmune diseases, immunosuppressive therapy during organ transplantation, childhood rhabdomyosarcoma and osteosarcoma, etc.
This report aims to provide a comprehensive presentation of the global market for Cyclophosphamide Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cyclophosphamide Injection. This report contains market size and forecasts of Cyclophosphamide Injection in global, including the following market information:
Global Cyclophosphamide Injection Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Cyclophosphamide Injection Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Cyclophosphamide Injection companies in 2022 (%)
The global Cyclophosphamide Injection market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
High-Dose Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Cyclophosphamide Injection include Baxter, Novartis, Amneal Pharmaceuticals, Aurobindo Pharma, Zydus Cadila, Pfizer, Athenex, GLS Pharma and NorthStar Rx LLC, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cyclophosphamide Injection manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cyclophosphamide Injection Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Cyclophosphamide Injection Market Segment Percentages, by Type, 2022 (%)
High-Dose
Low-Dose
Global Cyclophosphamide Injection Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Cyclophosphamide Injection Market Segment Percentages, by Application, 2022 (%)
Cancer
Autoimmune Diseases
AL Amyloidosis
Others
Global Cyclophosphamide Injection Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Cyclophosphamide Injection Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cyclophosphamide Injection revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Cyclophosphamide Injection revenues share in global market, 2022 (%)
Key companies Cyclophosphamide Injection sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Cyclophosphamide Injection sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Baxter
Novartis
Amneal Pharmaceuticals
Aurobindo Pharma
Zydus Cadila
Pfizer
Athenex
GLS Pharma
NorthStar Rx LLC
Jiangsu Hengrui Medicine
Getwell Oncology
Ingenus
Outline of Major Chapters:
Chapter 1: Introduces the definition of Cyclophosphamide Injection, market overview.
Chapter 2: Global Cyclophosphamide Injection market size in revenue and volume.
Chapter 3: Detailed analysis of Cyclophosphamide Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Cyclophosphamide Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Cyclophosphamide Injection capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Cyclophosphamide Injection Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Cyclophosphamide Injection Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Cyclophosphamide Injection Overall Market Size
2.1 Global Cyclophosphamide Injection Market Size: 2022 VS 2029
2.2 Global Cyclophosphamide Injection Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Cyclophosphamide Injection Sales: 2018-2029
3 Company Landscape
3.1 Top Cyclophosphamide Injection Players in Global Market
3.2 Top Global Cyclophosphamide Injection Companies Ranked by Revenue
3.3 Global Cyclophosphamide Injection Revenue by Companies
3.4 Global Cyclophosphamide Injection Sales by Companies
3.5 Global Cyclophosphamide Injection Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Cyclophosphamide Injection Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Cyclophosphamide Injection Product Type
3.8 Tier 1, Tier 2 and Tier 3 Cyclophosphamide Injection Players in Global Market
3.8.1 List of Global Tier 1 Cyclophosphamide Injection Companies
3.8.2 List of Global Tier 2 and Tier 3 Cyclophosphamide Injection Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Cyclophosphamide Injection Market Size Markets, 2022 & 2029
4.1.2 High-Dose
4.1.3 Low-Dose
4.2 By Type – Global Cyclophosphamide Injection Revenue & Forecasts
4.2.1 By Type – Global Cyclophosphamide Injection Revenue, 2018-2023
4.2.2 By Type – Global Cyclophosphamide Injection Revenue, 2024-2029
4.2.3 By Type – Global Cyclophosphamide Injection Revenue Market Share, 2018-2029
4.3 By Type – Global Cyclophosphamide Injection Sales & Forecasts
4.3.1 By Type – Global Cyclophosphamide Injection Sales, 2018-2023
4.3.2 By Type – Global Cyclophosphamide Injection Sales, 2024-2029
4.3.3 By Type – Global Cyclophosphamide Injection Sales Market Share, 2018-2029
4.4 By Type – Global Cyclophosphamide Injection Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Cyclophosphamide Injection Market Size, 2022 & 2029
5.1.2 Cancer
5.1.3 Autoimmune Diseases
5.1.4 AL Amyloidosis
5.1.5 Others
5.2 By Application – Global Cyclophosphamide Injection Revenue & Forecasts
5.2.1 By Application – Global Cyclophosphamide Injection Revenue, 2018-2023
5.2.2 By Application – Global Cyclophosphamide Injection Revenue, 2024-2029
5.2.3 By Application – Global Cyclophosphamide Injection Revenue Market Share, 2018-2029
5.3 By Application – Global Cyclophosphamide Injection Sales & Forecasts
5.3.1 By Application – Global Cyclophosphamide Injection Sales, 2018-2023
5.3.2 By Application – Global Cyclophosphamide Injection Sales, 2024-2029
5.3.3 By Application – Global Cyclophosphamide Injection Sales Market Share, 2018-2029
5.4 By Application – Global Cyclophosphamide Injection Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Cyclophosphamide Injection Market Size, 2022 & 2029
6.2 By Region – Global Cyclophosphamide Injection Revenue & Forecasts
6.2.1 By Region – Global Cyclophosphamide Injection Revenue, 2018-2023
6.2.2 By Region – Global Cyclophosphamide Injection Revenue, 2024-2029
6.2.3 By Region – Global Cyclophosphamide Injection Revenue Market Share, 2018-2029
6.3 By Region – Global Cyclophosphamide Injection Sales & Forecasts
6.3.1 By Region – Global Cyclophosphamide Injection Sales, 2018-2023
6.3.2 By Region – Global Cyclophosphamide Injection Sales, 2024-2029
6.3.3 By Region – Global Cyclophosphamide Injection Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Cyclophosphamide Injection Revenue, 2018-2029
6.4.2 By Country – North America Cyclophosphamide Injection Sales, 2018-2029
6.4.3 US Cyclophosphamide Injection Market Size, 2018-2029
6.4.4 Canada Cyclophosphamide Injection Market Size, 2018-2029
6.4.5 Mexico Cyclophosphamide Injection Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Cyclophosphamide Injection Revenue, 2018-2029
6.5.2 By Country – Europe Cyclophosphamide Injection Sales, 2018-2029
6.5.3 Germany Cyclophosphamide Injection Market Size, 2018-2029
6.5.4 France Cyclophosphamide Injection Market Size, 2018-2029
6.5.5 U.K. Cyclophosphamide Injection Market Size, 2018-2029
6.5.6 Italy Cyclophosphamide Injection Market Size, 2018-2029
6.5.7 Russia Cyclophosphamide Injection Market Size, 2018-2029
6.5.8 Nordic Countries Cyclophosphamide Injection Market Size, 2018-2029
6.5.9 Benelux Cyclophosphamide Injection Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Cyclophosphamide Injection Revenue, 2018-2029
6.6.2 By Region – Asia Cyclophosphamide Injection Sales, 2018-2029
6.6.3 China Cyclophosphamide Injection Market Size, 2018-2029
6.6.4 Japan Cyclophosphamide Injection Market Size, 2018-2029
6.6.5 South Korea Cyclophosphamide Injection Market Size, 2018-2029
6.6.6 Southeast Asia Cyclophosphamide Injection Market Size, 2018-2029
6.6.7 India Cyclophosphamide Injection Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Cyclophosphamide Injection Revenue, 2018-2029
6.7.2 By Country – South America Cyclophosphamide Injection Sales, 2018-2029
6.7.3 Brazil Cyclophosphamide Injection Market Size, 2018-2029
6.7.4 Argentina Cyclophosphamide Injection Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Cyclophosphamide Injection Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Cyclophosphamide Injection Sales, 2018-2029
6.8.3 Turkey Cyclophosphamide Injection Market Size, 2018-2029
6.8.4 Israel Cyclophosphamide Injection Market Size, 2018-2029
6.8.5 Saudi Arabia Cyclophosphamide Injection Market Size, 2018-2029
6.8.6 UAE Cyclophosphamide Injection Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Baxter
7.1.1 Baxter Company Summary
7.1.2 Baxter Business Overview
7.1.3 Baxter Cyclophosphamide Injection Major Product Offerings
7.1.4 Baxter Cyclophosphamide Injection Sales and Revenue in Global (2018-2023)
7.1.5 Baxter Key News & Latest Developments
7.2 Novartis
7.2.1 Novartis Company Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Cyclophosphamide Injection Major Product Offerings
7.2.4 Novartis Cyclophosphamide Injection Sales and Revenue in Global (2018-2023)
7.2.5 Novartis Key News & Latest Developments
7.3 Amneal Pharmaceuticals
7.3.1 Amneal Pharmaceuticals Company Summary
7.3.2 Amneal Pharmaceuticals Business Overview
7.3.3 Amneal Pharmaceuticals Cyclophosphamide Injection Major Product Offerings
7.3.4 Amneal Pharmaceuticals Cyclophosphamide Injection Sales and Revenue in Global (2018-2023)
7.3.5 Amneal Pharmaceuticals Key News & Latest Developments
7.4 Aurobindo Pharma
7.4.1 Aurobindo Pharma Company Summary
7.4.2 Aurobindo Pharma Business Overview
7.4.3 Aurobindo Pharma Cyclophosphamide Injection Major Product Offerings
7.4.4 Aurobindo Pharma Cyclophosphamide Injection Sales and Revenue in Global (2018-2023)
7.4.5 Aurobindo Pharma Key News & Latest Developments
7.5 Zydus Cadila
7.5.1 Zydus Cadila Company Summary
7.5.2 Zydus Cadila Business Overview
7.5.3 Zydus Cadila Cyclophosphamide Injection Major Product Offerings
7.5.4 Zydus Cadila Cyclophosphamide Injection Sales and Revenue in Global (2018-2023)
7.5.5 Zydus Cadila Key News & Latest Developments
7.6 Pfizer
7.6.1 Pfizer Company Summary
7.6.2 Pfizer Business Overview
7.6.3 Pfizer Cyclophosphamide Injection Major Product Offerings
7.6.4 Pfizer Cyclophosphamide Injection Sales and Revenue in Global (2018-2023)
7.6.5 Pfizer Key News & Latest Developments
7.7 Athenex
7.7.1 Athenex Company Summary
7.7.2 Athenex Business Overview
7.7.3 Athenex Cyclophosphamide Injection Major Product Offerings
7.7.4 Athenex Cyclophosphamide Injection Sales and Revenue in Global (2018-2023)
7.7.5 Athenex Key News & Latest Developments
7.8 GLS Pharma
7.8.1 GLS Pharma Company Summary
7.8.2 GLS Pharma Business Overview
7.8.3 GLS Pharma Cyclophosphamide Injection Major Product Offerings
7.8.4 GLS Pharma Cyclophosphamide Injection Sales and Revenue in Global (2018-2023)
7.8.5 GLS Pharma Key News & Latest Developments
7.9 NorthStar Rx LLC
7.9.1 NorthStar Rx LLC Company Summary
7.9.2 NorthStar Rx LLC Business Overview
7.9.3 NorthStar Rx LLC Cyclophosphamide Injection Major Product Offerings
7.9.4 NorthStar Rx LLC Cyclophosphamide Injection Sales and Revenue in Global (2018-2023)
7.9.5 NorthStar Rx LLC Key News & Latest Developments
7.10 Jiangsu Hengrui Medicine
7.10.1 Jiangsu Hengrui Medicine Company Summary
7.10.2 Jiangsu Hengrui Medicine Business Overview
7.10.3 Jiangsu Hengrui Medicine Cyclophosphamide Injection Major Product Offerings
7.10.4 Jiangsu Hengrui Medicine Cyclophosphamide Injection Sales and Revenue in Global (2018-2023)
7.10.5 Jiangsu Hengrui Medicine Key News & Latest Developments
7.11 Getwell Oncology
7.11.1 Getwell Oncology Company Summary
7.11.2 Getwell Oncology Cyclophosphamide Injection Business Overview
7.11.3 Getwell Oncology Cyclophosphamide Injection Major Product Offerings
7.11.4 Getwell Oncology Cyclophosphamide Injection Sales and Revenue in Global (2018-2023)
7.11.5 Getwell Oncology Key News & Latest Developments
7.12 Ingenus
7.12.1 Ingenus Company Summary
7.12.2 Ingenus Cyclophosphamide Injection Business Overview
7.12.3 Ingenus Cyclophosphamide Injection Major Product Offerings
7.12.4 Ingenus Cyclophosphamide Injection Sales and Revenue in Global (2018-2023)
7.12.5 Ingenus Key News & Latest Developments
8 Global Cyclophosphamide Injection Production Capacity, Analysis
8.1 Global Cyclophosphamide Injection Production Capacity, 2018-2029
8.2 Cyclophosphamide Injection Production Capacity of Key Manufacturers in Global Market
8.3 Global Cyclophosphamide Injection Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Cyclophosphamide Injection Supply Chain Analysis
10.1 Cyclophosphamide Injection Industry Value Chain
10.2 Cyclophosphamide Injection Upstream Market
10.3 Cyclophosphamide Injection Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Cyclophosphamide Injection Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Cyclophosphamide Injection in Global Market
Table 2. Top Cyclophosphamide Injection Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Cyclophosphamide Injection Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Cyclophosphamide Injection Revenue Share by Companies, 2018-2023
Table 5. Global Cyclophosphamide Injection Sales by Companies, (K Units), 2018-2023
Table 6. Global Cyclophosphamide Injection Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Cyclophosphamide Injection Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Cyclophosphamide Injection Product Type
Table 9. List of Global Tier 1 Cyclophosphamide Injection Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Cyclophosphamide Injection Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Cyclophosphamide Injection Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Cyclophosphamide Injection Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Cyclophosphamide Injection Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Cyclophosphamide Injection Sales (K Units), 2018-2023
Table 15. By Type - Global Cyclophosphamide Injection Sales (K Units), 2024-2029
Table 16. By Application – Global Cyclophosphamide Injection Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Cyclophosphamide Injection Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Cyclophosphamide Injection Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Cyclophosphamide Injection Sales (K Units), 2018-2023
Table 20. By Application - Global Cyclophosphamide Injection Sales (K Units), 2024-2029
Table 21. By Region – Global Cyclophosphamide Injection Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Cyclophosphamide Injection Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Cyclophosphamide Injection Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Cyclophosphamide Injection Sales (K Units), 2018-2023
Table 25. By Region - Global Cyclophosphamide Injection Sales (K Units), 2024-2029
Table 26. By Country - North America Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Cyclophosphamide Injection Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Cyclophosphamide Injection Sales, (K Units), 2018-2023
Table 29. By Country - North America Cyclophosphamide Injection Sales, (K Units), 2024-2029
Table 30. By Country - Europe Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Cyclophosphamide Injection Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Cyclophosphamide Injection Sales, (K Units), 2018-2023
Table 33. By Country - Europe Cyclophosphamide Injection Sales, (K Units), 2024-2029
Table 34. By Region - Asia Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Cyclophosphamide Injection Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Cyclophosphamide Injection Sales, (K Units), 2018-2023
Table 37. By Region - Asia Cyclophosphamide Injection Sales, (K Units), 2024-2029
Table 38. By Country - South America Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Cyclophosphamide Injection Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Cyclophosphamide Injection Sales, (K Units), 2018-2023
Table 41. By Country - South America Cyclophosphamide Injection Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Cyclophosphamide Injection Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Cyclophosphamide Injection Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Cyclophosphamide Injection Sales, (K Units), 2024-2029
Table 46. Baxter Company Summary
Table 47. Baxter Cyclophosphamide Injection Product Offerings
Table 48. Baxter Cyclophosphamide Injection Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. Baxter Key News & Latest Developments
Table 50. Novartis Company Summary
Table 51. Novartis Cyclophosphamide Injection Product Offerings
Table 52. Novartis Cyclophosphamide Injection Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. Novartis Key News & Latest Developments
Table 54. Amneal Pharmaceuticals Company Summary
Table 55. Amneal Pharmaceuticals Cyclophosphamide Injection Product Offerings
Table 56. Amneal Pharmaceuticals Cyclophosphamide Injection Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. Amneal Pharmaceuticals Key News & Latest Developments
Table 58. Aurobindo Pharma Company Summary
Table 59. Aurobindo Pharma Cyclophosphamide Injection Product Offerings
Table 60. Aurobindo Pharma Cyclophosphamide Injection Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. Aurobindo Pharma Key News & Latest Developments
Table 62. Zydus Cadila Company Summary
Table 63. Zydus Cadila Cyclophosphamide Injection Product Offerings
Table 64. Zydus Cadila Cyclophosphamide Injection Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. Zydus Cadila Key News & Latest Developments
Table 66. Pfizer Company Summary
Table 67. Pfizer Cyclophosphamide Injection Product Offerings
Table 68. Pfizer Cyclophosphamide Injection Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. Pfizer Key News & Latest Developments
Table 70. Athenex Company Summary
Table 71. Athenex Cyclophosphamide Injection Product Offerings
Table 72. Athenex Cyclophosphamide Injection Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. Athenex Key News & Latest Developments
Table 74. GLS Pharma Company Summary
Table 75. GLS Pharma Cyclophosphamide Injection Product Offerings
Table 76. GLS Pharma Cyclophosphamide Injection Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. GLS Pharma Key News & Latest Developments
Table 78. NorthStar Rx LLC Company Summary
Table 79. NorthStar Rx LLC Cyclophosphamide Injection Product Offerings
Table 80. NorthStar Rx LLC Cyclophosphamide Injection Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. NorthStar Rx LLC Key News & Latest Developments
Table 82. Jiangsu Hengrui Medicine Company Summary
Table 83. Jiangsu Hengrui Medicine Cyclophosphamide Injection Product Offerings
Table 84. Jiangsu Hengrui Medicine Cyclophosphamide Injection Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 85. Jiangsu Hengrui Medicine Key News & Latest Developments
Table 86. Getwell Oncology Company Summary
Table 87. Getwell Oncology Cyclophosphamide Injection Product Offerings
Table 88. Getwell Oncology Cyclophosphamide Injection Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 89. Getwell Oncology Key News & Latest Developments
Table 90. Ingenus Company Summary
Table 91. Ingenus Cyclophosphamide Injection Product Offerings
Table 92. Ingenus Cyclophosphamide Injection Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 93. Ingenus Key News & Latest Developments
Table 94. Cyclophosphamide Injection Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 95. Global Cyclophosphamide Injection Capacity Market Share of Key Manufacturers, 2021-2023
Table 96. Global Cyclophosphamide Injection Production by Region, 2018-2023 (K Units)
Table 97. Global Cyclophosphamide Injection Production by Region, 2024-2029 (K Units)
Table 98. Cyclophosphamide Injection Market Opportunities & Trends in Global Market
Table 99. Cyclophosphamide Injection Market Drivers in Global Market
Table 100. Cyclophosphamide Injection Market Restraints in Global Market
Table 101. Cyclophosphamide Injection Raw Materials
Table 102. Cyclophosphamide Injection Raw Materials Suppliers in Global Market
Table 103. Typical Cyclophosphamide Injection Downstream
Table 104. Cyclophosphamide Injection Downstream Clients in Global Market
Table 105. Cyclophosphamide Injection Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Cyclophosphamide Injection Segment by Type in 2022
Figure 2. Cyclophosphamide Injection Segment by Application in 2022
Figure 3. Global Cyclophosphamide Injection Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Cyclophosphamide Injection Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Cyclophosphamide Injection Revenue, 2018-2029 (US$, Mn)
Figure 7. Cyclophosphamide Injection Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Cyclophosphamide Injection Revenue in 2022
Figure 9. By Type - Global Cyclophosphamide Injection Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Cyclophosphamide Injection Revenue Market Share, 2018-2029
Figure 11. By Type - Global Cyclophosphamide Injection Sales Market Share, 2018-2029
Figure 12. By Type - Global Cyclophosphamide Injection Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Cyclophosphamide Injection Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Cyclophosphamide Injection Revenue Market Share, 2018-2029
Figure 15. By Application - Global Cyclophosphamide Injection Sales Market Share, 2018-2029
Figure 16. By Application - Global Cyclophosphamide Injection Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Cyclophosphamide Injection Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Cyclophosphamide Injection Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Cyclophosphamide Injection Revenue Market Share, 2018-2029
Figure 20. By Region - Global Cyclophosphamide Injection Sales Market Share, 2018-2029
Figure 21. By Country - North America Cyclophosphamide Injection Revenue Market Share, 2018-2029
Figure 22. By Country - North America Cyclophosphamide Injection Sales Market Share, 2018-2029
Figure 23. US Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Cyclophosphamide Injection Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Cyclophosphamide Injection Sales Market Share, 2018-2029
Figure 28. Germany Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2029
Figure 29. France Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Cyclophosphamide Injection Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Cyclophosphamide Injection Sales Market Share, 2018-2029
Figure 37. China Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2029
Figure 41. India Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Cyclophosphamide Injection Revenue Market Share, 2018-2029
Figure 43. By Country - South America Cyclophosphamide Injection Sales Market Share, 2018-2029
Figure 44. Brazil Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Cyclophosphamide Injection Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Cyclophosphamide Injection Sales Market Share, 2018-2029
Figure 48. Turkey Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Cyclophosphamide Injection Revenue, (US$, Mn), 2018-2029
Figure 52. Global Cyclophosphamide Injection Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Cyclophosphamide Injection by Region, 2022 VS 2029
Figure 54. Cyclophosphamide Injection Industry Value Chain
Figure 55. Marketing Channels

※参考情報

シクロホスファミド注射は、化学療法において広く使用される薬剤の一つで、その主成分であるシクロホスファミドは、アルキル化剤に分類される抗腫瘍薬です。この薬剤は、小さな分子構造を持ち、DNAに結合することで細胞の増殖を抑制します。シクロホスファミドは、特に悪性腫瘍の治療において重要な役割を果たしています。

シクロホスファミドの特徴としては、その効果的な抗腫瘍作用と、比較的広範囲にわたる適応症があります。この薬は、特にリンパ腫、白血病、乳癌、卵巣癌、小細胞肺癌など、さまざまな種類の癌に対して使用されます。また、自己免疫疾患に対しても用いられることがあります。過剰な免疫反応を抑制する効果があるため、全身性エリテマトーデスや多発性硬化症といった疾患の治療にも利用されています。

シクロホスファミドは、経口投与だけでなく、注射によっても投与されるため、患者の状態に応じた柔軟な使用が可能です。注射での投与は、薬の吸収が迅速であるため、急性の治療が必要な場合にも適しています。シクロホスファミド注射は、通常、静脈内に直接投与されますが、経皮的または筋肉内投与が可能な場合もあります。

使用に際しては、シクロホスファミドの投与量や頻度は、患者の年齢、体重、病状、および他の治療との組み合わせによって異なるため、医師によって適宜調整されます。一般的には、サイクルごとに休薬期間を設け、腫瘍細胞に対する効果を最大限に引き出すようにします。この薬剤の治療効果は、数週間から数ヶ月にわたって現れることが多いですが、患者ごとに異なるため、定期的な診察とモニタリングが不可欠です。

シクロホスファミドの投与に関連する副作用も考慮する必要があります。一般的な副作用には、脱毛、消化器系の問題（つわり、下痢）、骨髄抑制（血液細胞の生成が低下することで感染症のリスクが高まるなど）、免疫系への影響、さらには長期的には二次癌のリスクがあることが含まれます。これらの副作用は、患者によって程度が異なり、治療の進行に応じて管理されるべきです。

シクロホスファミドの使用に関連する研究は常に進行中であり、新しい治療方法や投与法の開発が期待されています。また、個別化医療の観点から、患者の遺伝的背景や腫瘍の特性に基づいた治療法の確立が目指されています。例えば、シクロホスファミドに対する感受性が高い腫瘍タイプの発見や、耐性のメカニズムの解明が進むことで、より効果的な治療法の開発が期待されています。

さらに、シクロホスファミドは、他の化学療法薬や新規治療法と組み合わせて使用されることが多く、そのシナジー効果を活かすことで治療効果を最大限に引き出す試みが行われています。最近では、免疫療法や標的療法と併用することで、癌治療の新たな戦略が模索されています。これにより、シクロホスファミドの適応症は今後も拡大していく可能性があります。

このように、シクロホスファミド注射は、多様な癌や自己免疫疾患に対して効果的に作用する治療法ですが、その使用には注意が必要です。副作用を管理しながら、患者個々の状況に応じた最適な治療法を提供することが、今後の課題となっています。治療に際しては、医療従事者の適切な指導と患者自身の理解が不可欠であり、共に戦う姿勢が重要です。シクロホスファミドを含む化学療法が、今後も多くの患者の希望となることを願っています。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ シクロホスファミド注射の世界市場見通し2023年-2029年(Cyclophosphamide Injection Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

シクロホスファミド注射の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp